Corcept (CORT) Reports Q1 2026 Earnings with Revenue Growth and Guidance Increase
Corcept Therapeutics (CORT) reported Q1 2026 earnings with total revenue of $164.9 million, up from $157.2 million in the previous year. The company raised its 2026 revenue guidance to $950 million to $1.05 billion, driven by growth in its endocrine business. However, the company reported a net loss of $31.8 million for the quarter, compared to a net income of $20.5 million in Q1 2025.
Tickers: $CORT
Topics: clinical trials earnings FDA approval net loss revenue stock performance